Leading medical associations support pharmacogenetic testing
When it comes to prescribing drugs and evaluating patients for potential drug interactions, pharmacogenetic testing is widely endorsed by many influential organizations.
The Clinical Pharmacogenetics Implementation Consortium provides numerous peer-reviewed guidelines on pharmacogenetics designed to help healthcare providers understand how genetic test results should be used to optimize drug therapy.
The Dutch Pharmacogenetics Working Group has developed pharmacogenetics-based therapeutic (dose) recommendations, which are integrated into computerized systems for drug prescription and automated medication surveillance.
The American Medical Association encourages healthcare providers to become familiar with genetic variations that can affect patients’ drug metabolism, and be able to recognize when testing should be used to inform prescribing.
The Food and Drug Administration currently recommends testing in specific instances (to determine the starting dose for warfarin, for example), and is laying the groundwork for routine testing in early phase clinical drug trials.
The American Psychiatric Association established a memorial lecture to honor David A. Mrazek. The lecture is an annual award given to individuals based on their pharmacogenomic research and their ability to relate findings to a clinical audience.
The American Society of Health-System Pharmacists believes that pharmacogenetic testing can improve medication-related outcomes across the continuum of care in all health-system practice settings.
A report from the U.S. Department of Health and Human Services states: “Pharmacogenetic testing for potential adverse drug reactions (ADRs) or ineffective drug responses may reduce health care costs over the long term by diminishing the duration and severity of illness and the costs associated with ineffective treatment and avoidable ADRs.”